On the role of tumor heterogeneity for optimal cancer chemotherapy

  • Received: 01 April 2018 Revised: 01 October 2018
  • Primary: 92C50, 49K15; Secondary: 93C15

  • We review results about the influence tumor heterogeneity has on optimal chemotherapy protocols (relative to timing, dosing and sequencing of the agents) that can be inferred from mathematical models. If a tumor consists of a homogeneous population of chemotherapeutically sensitive cells, then optimal protocols consist of upfront dosing of cytotoxic agents at maximum tolerated doses (MTD) followed by rest periods. This structure agrees with the MTD paradigm in medical practice where drug holidays limit the overall toxicity. As tumor heterogeneity becomes prevalent and sub-populations with resistant traits emerge, this structure no longer needs to be optimal. Depending on conditions relating to the growth rates of the sub-populations and whether drug resistance is intrinsic or acquired, various mathematical models point to administrations at lower than maximum dose rates as being superior. Such results are mirrored in the medical literature in the emergence of adaptive chemotherapy strategies. If conditions are unfavorable, however, it becomes difficult, if not impossible, to limit a resistant population from eventually becoming dominant. On the other hand, increased heterogeneity of tumor cell populations increases a tumor's immunogenicity and immunotherapies may provide a viable and novel alternative for such cases.

    Citation: Urszula Ledzewicz, Heinz Schättler, Shuo Wang. On the role of tumor heterogeneity for optimal cancer chemotherapy[J]. Networks and Heterogeneous Media, 2019, 14(1): 131-147. doi: 10.3934/nhm.2019007

    Related Papers:

    [1] Urszula Foryś, Jan Poleszczuk . A delay-differential equation model of HIV related cancer--immune system dynamics. Mathematical Biosciences and Engineering, 2011, 8(2): 627-641. doi: 10.3934/mbe.2011.8.627
    [2] Katrine O. Bangsgaard, Morten Andersen, Vibe Skov, Lasse Kjær, Hans C. Hasselbalch, Johnny T. Ottesen . Dynamics of competing heterogeneous clones in blood cancers explains multiple observations - a mathematical modeling approach. Mathematical Biosciences and Engineering, 2020, 17(6): 7645-7670. doi: 10.3934/mbe.2020389
    [3] Thanh Nam Nguyen, Jean Clairambault, Thierry Jaffredo, Benoît Perthame, Delphine Salort . Adaptive dynamics of hematopoietic stem cells and their supporting stroma: a model and mathematical analysis. Mathematical Biosciences and Engineering, 2019, 16(5): 4818-4845. doi: 10.3934/mbe.2019243
    [4] Jie Lou, Tommaso Ruggeri, Claudio Tebaldi . Modeling Cancer in HIV-1 Infected Individuals: Equilibria, Cycles and Chaotic Behavior. Mathematical Biosciences and Engineering, 2006, 3(2): 313-324. doi: 10.3934/mbe.2006.3.313
    [5] J. Ignacio Tello . On a mathematical model of tumor growth based on cancer stem cells. Mathematical Biosciences and Engineering, 2013, 10(1): 263-278. doi: 10.3934/mbe.2013.10.263
    [6] Abeer S. Alnahdi, Muhammad Idrees . Nonlinear dynamics of estrogen receptor-positive breast cancer integrating experimental data: A novel spatial modeling approach. Mathematical Biosciences and Engineering, 2023, 20(12): 21163-21185. doi: 10.3934/mbe.2023936
    [7] Eminugroho Ratna Sari, Fajar Adi-Kusumo, Lina Aryati . Mathematical analysis of a SIPC age-structured model of cervical cancer. Mathematical Biosciences and Engineering, 2022, 19(6): 6013-6039. doi: 10.3934/mbe.2022281
    [8] Haifeng Zhang, Jinzhi Lei . Optimal treatment strategy of cancers with intratumor heterogeneity. Mathematical Biosciences and Engineering, 2022, 19(12): 13337-13373. doi: 10.3934/mbe.2022625
    [9] Qiaojun Situ, Jinzhi Lei . A mathematical model of stem cell regeneration with epigenetic state transitions. Mathematical Biosciences and Engineering, 2017, 14(5&6): 1379-1397. doi: 10.3934/mbe.2017071
    [10] Hongli Yang, Jinzhi Lei . A mathematical model of chromosome recombination-induced drug resistance in cancer therapy. Mathematical Biosciences and Engineering, 2019, 16(6): 7098-7111. doi: 10.3934/mbe.2019356
  • We review results about the influence tumor heterogeneity has on optimal chemotherapy protocols (relative to timing, dosing and sequencing of the agents) that can be inferred from mathematical models. If a tumor consists of a homogeneous population of chemotherapeutically sensitive cells, then optimal protocols consist of upfront dosing of cytotoxic agents at maximum tolerated doses (MTD) followed by rest periods. This structure agrees with the MTD paradigm in medical practice where drug holidays limit the overall toxicity. As tumor heterogeneity becomes prevalent and sub-populations with resistant traits emerge, this structure no longer needs to be optimal. Depending on conditions relating to the growth rates of the sub-populations and whether drug resistance is intrinsic or acquired, various mathematical models point to administrations at lower than maximum dose rates as being superior. Such results are mirrored in the medical literature in the emergence of adaptive chemotherapy strategies. If conditions are unfavorable, however, it becomes difficult, if not impossible, to limit a resistant population from eventually becoming dominant. On the other hand, increased heterogeneity of tumor cell populations increases a tumor's immunogenicity and immunotherapies may provide a viable and novel alternative for such cases.



    Myeloproliferative Neoplasms (MPNs) is a group of hematopoietic stem cell disorders, including essential thrombocytosis (ET), polycythemia vera (PV) and primary myelofibrosis (PMF) [1,2]. The pathogenesis of these neoplasms is yet to be fully discovered. For patients with MPNs, the mutation $ JAK2 $V617F is found present in the most cases of ET (50%) and in 95% of the cases with PV and PMF ultimately leading to acute myeloid leukemia (AML) [3,4]. This suggests a biological continuum where the diseases evolve from early cancers (ET and PV) into the advanced myelofibrosis stage, with an increasing load of $ JAK2 $V617F mutations from a low burden at ET and PV to a high load [2,5]. MPNs imply an increased risk for the development of other cancers [1,4].

    Recent research supports that MPNs can be regarded as chronic inflammatory diseases and MPNs has been described as a "human inflammation model", which leads to premature atherosclerosis, clonal evolution and an increased risk of second cancers. [2,3,6]. This is based on evidence from clinical observations, experiments and molecular studies [3].

    Several insightful theoretical studies have been published on control dynamics of biological networks. Mathematical models have been proposed [7,8,9] describing the control networks for regulation of stem cell lineage.Mathematical modelling of cancer is useful for understanding of cancer initiation, progression [10,11], to confirm or dismiss biological/medical hypotheses, and to study effects of single or multi modality treatments in silico. The mathematical model presented in [12] shows that successful therapy may eliminate tumour stem cells. A five-dimensional model given in [13] includes active and quiescent stem cells, progenitor cells, mature cells and one immune compartment describing chronic myelogenous leukemia.In [14] a mathematical model of cancer stem cell dynamics is proposed and the different scenarios of cancer initiation and possible treatments strategies have been discussed. The mathematical model given in [15] is useful for investigating the impact of cytokine-dependence of acute myeloid leukemic cells. In addition, the model allows distinguishing between cytokine-dependent and cytokine-independent acute myeloid leukemia (AML) and both scenarios are supported by patient data.

    However, only a few mathematical models of MPNs exist. Some work includes investigation of the origin of myeloid malignancies with MPNs as a particular example [16]. In [17], a two dimensional model of MPNs is investigated without including the immune response dynamically. The Cancitis model including chronic inflammation as the trigger and driver of MPNs was proposed in [5]. In [5], T-cells are not explicitly considered whereas, in [18], the effect of these cells has been included specifically. The analysis of a two dimensional mathematical model [18] is used to discuss in silico effect of existing and novel treatments. The model presented here is identical to the model presented in [5] except for the simpler functional form of the stem cells niche interaction used here and in [18].

    In the present paper we conduct a thorough mathematical investigation of the Cancitis model and explore the intricate coupling between inflammation and MPNs. We address the following questions which have not been systematically investigated previously: Which steady states of the system are feasible and which trajectories are attracted to the steady states? How do the number and stability of the steady states change when varying the parameters, in particular, the exogenous inflammatory stimuli, self-renewal and death rates of stem cells, and inhibitory strength of the stem cell niche interaction? Which set of clustered parameters control the dynamics of the system? Does the analysis suggest correlated parameters? The bio-medical applications of the model analysis are discussed, e.g. how the inflammation influences the transition between healthy and diseased states. In addition, the analysis predicts effects of ongoing and potential combination therapies.

    The Cancitis model stated in [5] is illustrated in Figure 1, with the system of differential equations shown in system (2.1). In this section the details of the model and the reasoning behind it is presented.

    Figure 1.  The boxes illustrate the compartments of the Cancitis model. The arrows represent the rates of the flows between and out of these compartments. Red stipulated arrows represent the effect of inflammation which is stimulated by exogenous inflammatory stimuli, $ I $. Green stipulated lines represent the bone marrow niches interaction with a 'crowding' competition between HSC and MSC. Stem cells (HSC and MSC) may self-renew, die or differentiate, while mature cells die after a while (MMC, HMC). Dead cells ($ a $) are engulfed by the immune cells ($ s $), that stimulate production of stem cells, increase risk of mutation and increase the removal of dead cells (For more details, see main text).

    The model describes the proliferation of hematopoietic stem cells (HSC) into hematopoietic mature cells (HMC) and likewise malignant stem cells (MSC) into malignant mature cells (MMC). Additionally, the model considers the number of dead cells and the level of inflammation. The debris from the dead cells stimulates the immune response, which in turn affects the self-renewal rate of both HSCs and MSCs.

    The model consists of six ordinary differential equations one for each compartment; the number of HSC ($ x_0 $), the number of HMC ($ x_1 $), the number of MSC ($ y_0 $), the number of MMC ($ y_1 $), the number of dead cells ($ a $), and the level of inflammation ($ s $).

    The equations are of the general form,

    $ \left\{ Change in amount of acompartment per time
    \right\} = \left\{ rate of production timesthe producing source 
    \right\}-\left\{ rate of elimination times theamount in the compartment
    \right\}. $

    and read specifically,

    $ ˙x0=rx(ϕxsαx)x0rmsx0,
    $
    (2.1a)
    $ ˙x1=axAxx0dx1x1,
    $
    (2.1b)
    $ ˙y0=ry(ϕysαy)y0+rmsx0,
    $
    (2.1c)
    $ ˙y1=ayAyy0dy1y1,
    $
    (2.1d)
    $ ˙a=dx0x0+dy0y0+dx1x1+dy1y1eaas,
    $
    (2.1e)
    $ ˙s=rsaess+I,
    $
    (2.1f)

    with

    $ αx=dx0+axrxandαy=dy0+ayry.
    $
    (2.2)

    The expressions for the inhibitory niche feedback are chosen as Michaelis-Menten-like functions in contrast to [5],

    $ ϕxϕx(x0,y0)=11+cxxx0+cxyy0,
    $
    (2.3a)
    $ ϕyϕy(x0,y0)=11+cyxx0+cyyy0.
    $
    (2.3b)

    A stem cell can proliferate in three ways; symmetric self-renewal (resulting in two new stem cells), asymmetric self-renewal (resulting in one stem cell and one progenitor cell) and symmetric differentiation (resulting in two progenitor cells). The rate of self-renewal is denoted as $ r_x $ and $ r_y $ for HSC and MSC respectively. The self-renewal of stem cells is known to be inhibited by self-regulating niche feedback [19], resulting in decreased self-renewal when the level of stem cells in the bone marrow is high. Adopting the approach taken in [12], [20] and [21], this is implemented by Michaelis-Menten-like functions $ \phi_x(x_0, y_0) $ and $ \phi_y(x_0, y_0) $, shown in Eq (2.3b). Allowing the feedback to be different for HSC and MSC, the constants $ c_{xx} $ and $ c_{xy} $ capture the effects of HSC and MSC on the self-renewal of HSC, while $ c_{yx} $ and $ c_{yy} $ capture the corresponding effects on the self-renewal of MSC. Additionally, the inflammatory level also affects the self-renewal [22,23]. This leads a to self-renewal term per cell of $ r_x \phi_x s $ and $ r_y \phi_y s $ for HSC and MSC respectively. The parameter $ c_{ij} $ describes the inhibitory strength of the signalling bone marrow niche feedback from cell type $ j $ onto cell type $ i $. It is generally assumed that $ c_{yy}\leq c_{yx} \leq c_{xy} \leq c_{xx} $, since malignant cells are less sensitive to inhibitive niche feedback than hematopoietic cells [22,24].

    In [25], a multi compartmental model is proposed relying on a single external feedback mechanism. It is shown that the equilibrium level of mature cells depends only on the self-renewal parameters for the HSC and it is independent of the other compartments. Therefore, the progenitor cells are considered as intermediate steps between stem cells and mature cells, and are implicitly accounted for by multiplication factors $ A_x $ and $ A_y $ for HSC and MSC respectively. The rate at which the HSC reduces in transforming to HMC is denoted by $ a_x $ while the similar rate for MSC transforming to MMC is denoted by $ a_y $. As such, the HMC and MMC accordingly increase with rates $ a_x A_x $ and $ a_y A_y $ respectively. To account for the cell apoptosis, the four types of cells are removed with rates $ d_{x_0} $, $ d_{x_1} $, $ d_{y_0} $ and $ d_{y_1} $, for the corresponding cell types.

    Genetic mutations are by nature to be described as Poisson processes [26,27,28,29]. However, not all mutations are malignant; only mutation which happens on a particular location of the DNA, i.e. at specific amino acids causes a specific mutation, e.g. the JAK2V617F mutation. The probability for hitting a specific location is about 1/30000. In [30] the average mutation probability is estimated to 0.0035 per year, which corresponds to a specific mutation probability of $ 0.0035/30000 = 1.2 10^{-7} $ per year. Thus, the probability for one specific malignant mutation is about $ 10^{-7} $ per cell per year. Moreover, the mutation is affected by the inflammation, $ s $ [31,32], which is explicitly stated, and resulting in the effective mutation rate $ r_m s $. Assuming three sequential mutations are needed to generate a specific malignant stem cell the resulting probability becomes much higher ($ 10^{-25} $ per year per cell if the mutations are assumed independent). This could be implemented in the otherwise deterministic model but it would increase the computational cost, since it depends on both the probability of a single cell mutation and the number of potential mutating cells at a given time, which itself is determined by the preceding mutational history. To avoid such complications we initialize by having a single MSC and none MMC, and put the mutation rate to zero. This is justified by the fact that the probability of a single cell mutating is small compared to the self-renewal of the MSCs. Thus, the first mutation drives the development leaving a later identical mutation insignificant to the dynamics, which is confirmed by numerical simulations.

    The number of dead cells has an up-regulatory effect on the immune response denoted $ r_s $. External environmental factors also influence the inflammatory level. This is captured in the model by the term $ I $. Throughout we take $ I > 0 $, as a perfect sterile environment is an utopic idealization. This term may vary over time due to environmental changes, but in our mathematical analysis we will consider $ I $ as piecewise constant. The inflammation, $ s $, is down-regulated naturally by the eliminating rate $ e_s $.

    Additionally, the change in the amount of dead cells per time is given by the death rate times the number of cells minus the clearance by the immune system. As given in [33] clearance is described by a second order equation $ -e_a a s $ since the engulfed immune cells have to meet the dead cells debris to mediate endocytosis. Thus, clearance is bilinear in both $ a $ and $ s $ representing the activity of the immune system, eliminating the dead cells with an elimination rate $ e_a $.

    Initial conditions for the Cancitis model in equations are needed for the given system of differential equations (2.1–2.3b). Here, we mainly focus on the model after the first mutation, i.e. with $ y_0(0) = 1 $, $ y_1(0) = 0 $, $ r_m = 0 $, and the remaining variables as those in the healthy steady state (see below). All other parameter values are assumed to be positive.

    The stable steady states are attractors in the six dimensional phase space. This motivates systematic study of the existence and location of steady states and how this is affected by perturbing parameter values.

    Motivated by the biology where the number of cells and concentrations are required to be non-negative numbers, we will use the terminology that a steady state is admissible if and only if all the components are non-negative, i.e. if and only if a steady state is in the non-negative octahedron.

    Consider the system of Eqs (2.1–2.3b). For steady state solutions, $ \dot{x}_0 = \dot{x}_1 = \dot{y}_0 = \dot{y}_1 = \dot{a} = \dot{s} = 0 $,

    $ (ˉsαx(1+cxxˉx0+cxyˉy0))ˉx0=0,
    $
    (2.4a)
    $ (ˉsαy(1+cyxˉx0+cyyˉy0))ˉy0=0,
    $
    (2.4b)
    $ ˉx1=axAxˉx0dx1,
    $
    (2.4c)
    $ ˉy1=ayAyˉy0dy1,
    $
    (2.4d)
    $ dx0ˉx1+dx1ˉx1+dy0ˉy0+dy1ˉy1eaˉaˉs=0,
    $
    (2.4e)
    $ ˉa=esrs(ˉsIes).
    $
    (2.4f)

    The values of $ x_0 $, $ x_1 $, $ y_0 $, $ y_1 $, $ a $ and $ s $ at steady state are denoted as $ \bar{x}_0 $, $ \bar{x}_1 $, $ \bar{y}_0 $, $ \bar{y}_1 $, $ \bar{a} $ and $ \bar{s} $ respectively. The admissible steady states can be classified as,

    ● a trivial steady state if and only if $ \bar{x}_0 = \bar{y}_0 = 0 $,

    ● a (purely) hematopoietic steady state if and only if $ \bar{y}_0 = 0 $ and $ \bar{x}_0 > 0 $,

    ● a (purely) malignant steady state if and only if $ \bar{x}_0 = 0 $ and $ \bar{y}_0 > 0 $, or

    ● a co-existing steady state if and only if $ \bar{x}_0 > 0 $ and $ \bar{y}_0 > 0 $.

    The admissibility of steady states necessitates certain inequalities to be fulfilled, which leads to restriction on the parameters, e.g. from Eq (2.4f), non-negativity of $ \bar{a} $ requires $ \bar{s} \geq \frac{I}{e_s} $. $ I $ is assumed to be positive thus $ \frac{I}{e_s} > 0 $. Hence

    $ ˉsIes>0,
    $
    (2.5)

    for any admissible steady state. Note that, $ \bar{x}_1 $ and $ \bar{y}_1 $ are non-negative if and only if $ \bar{x}_0 $ and $ \bar{y}_0 $ are non-negative, respectively. Substituting expressions of $ \bar{x}_1 $ and $ \bar{y}_1 $ in Eq (2.4e) gives,

    $ eaˉaˉs=βxˉx0+βyˉy0,
    $
    (2.6)

    where $ \beta_x = a_x A_x+d_{x0} $ and $ \beta_y = a_y A_y+ d_{y0} $. Thus, Eqs (2.4e–2.4f) and (2.6) result in a second order equation in $ \bar{s} $ having the general solution,

    $ ˉs±=I2es(1±1+ζ(βxˉx0+βyˉy0)),
    $
    (2.7)

    where $ \zeta = \frac{4 r_s e_s}{e_a I^2} > 0 $. $ \bar{s}_- $ is negative for positive $ \bar{x}_0 $ or $ \bar{y}_0 $. In case, $ (\bar{x}_0, \bar{y}_0) = (0, 0) $, Eq (2.7) leads to $ \bar{s}_{-} = 0 $ contradicting $ \bar{s} > 0 $. Thus, $ s = \bar{s}_- $ is not biologically realizable and we therefore put $ \bar{s} = \bar{s}_+ $ in the further analysis. Note that, for non-trivial steady states, $ \bar{s} > \frac{I}{e_s} $. In addition, non-negativity of $ \bar{x}_0 $ and $ \bar{y}_0 $ implies non-negativity of $ \bar{x}_1 $, $ \bar{y}_1 $, $ \bar{s} $ and $ \bar{a} $.

    Hence, the existence of admissible steady states $ \bar{x}_0 $, $ \bar{y}_0 $, $ \bar{x}_1 $, $ \bar{y}_1 $, $ \bar{s} $ and $ \bar{a} $ follows from Eqs (2.4a), (2.4b) and (2.7).

    Below we make a complete analysis of the existence of various steady states depending on how $ I $ relates to the remaining parameters. This choice is due to the fact that the external inflammatory stimuli $ I $ is of great interest in health care and to elucidate consequences of using inflammation inhibitors as part of treatment.

    Proposition 1. A trivial steady state $ E_{0} $ always exists,

    $ E0=(0,0,0,0,0,Ies).
    $
    (2.8)

    Proof. Follow directly from Eqs (2.4e) and (2.5).

    Hematopoietic steady states may exist depending on the rest of the parameter values. As above we chose the inflammatory stimuli $ I $ as the leading parameter and make a complete analysis of possible hematopoietic steady states. The analysis of the existence of the hematopoietic steady states depends crucially on the following lumped parameters,

    $ IH=2esrsβxeacxxrsβxeacxxαx,
    $
    (2.9)
    $ ζH1=2esαxrsβxeacxxαx,
    $
    (2.10)
    $ ζH2=esαx,
    $
    (2.11)
    $ ζH3=rsβxeseacxx,
    $
    (2.12)

    the last two always being positive.

    Proposition 2. Two hematopoietic steady states $ E_{H\pm} $ may exist in the following cases,

    If $ \alpha_x^2 \leq \frac{\zeta_{H3}}{4} $ then $ E_{H+} $ exists if and only if $ I > 0 $.

    If $ \frac{\zeta_{H3}}{4} < \alpha_x^2 \leq \zeta_{H3} $ then $ E_{H+} $ exists if and only if $ I \geq I_{H} $.

    If $ \zeta_{H3} < \alpha_x^2 $ then $ E_{H+} $ exists if and only if $ I > \zeta_{H2} $.

    If $ \alpha_x^2 \leq \frac{\zeta_{H3}}{4} $ then $ E_{H-} $ exists if and only if $ I \leq \zeta_{H2} $.

    If $ \frac{\zeta_{H3}}{4} < \alpha_x^2 \leq \zeta_{H3} $ then $ E_{H-} $ exists if and only if $ I_{H} \leq I \leq \zeta_{H2} $.

    If $ \zeta_{H3} < \alpha_x^2 $ then $ E_{H-} $ does not exist.

    In case of existence, $ E_{H+} = (\bar{x}_{0H+}, \bar{x}_{1H+}, 0, 0, \bar{a}_{H+}, \bar{s}_{H+}) $ is given by $ \bar{x}_{0H+} = \frac{1}{2 e_s c_{xx}\alpha_x} \left(I-\zeta_{H1} + \sqrt{(\zeta_{H1}-I)^2-4 e_s \alpha_x(\zeta_{H2}-I)}\right) $, $ \bar{s}_{H+} = \alpha_x (1+c_{xx} \bar{x}_{0H+}) $, $ \bar{a}_{H+} = \frac{\beta_x \bar{x}_{0H+}}{e_a \bar{s}_{H+}} $, and $ \bar{x}_{1H+} = \frac{a_x A_x \bar{x}_{0H+}}{d_{x1}} $ whereas $ E_{H-} = (\bar{x}_{0H-}, \bar{x}_{0H-}, 0, 0, \bar{a}_{H-}, \bar{s}_{H-}) $ is given by $ \bar{x}_{0H-} = \frac{1}{2 e_s c_{xx}\alpha_x} \left(I-\zeta_{H1} - \sqrt{(\zeta_{H1}-I)^2-4 e_s \alpha_x(\zeta_{H2}-I)}\right) $, $ \bar{s}_{H-} = \alpha_x (1+c_{xx} \bar{x}_{0H-}) $, $ \bar{a}_{H-} = \frac{\beta_x \bar{x}_{0H-}}{e_a \bar{s}_{H-}} $, and $ \bar{x}_{1H-} = \frac{a_x A_x \bar{x}_{0H-}}{d_{x1}} $.

    Proof. A hematopoietic steady state $ E_{H} $ follows from Eqs (2.4a) and (2.7) with $ y_0 = y_1 = 0 $ as possible positive solutions to

    $ ˉx20H+1escxxαx(ζH1I)ˉx0H+1esc2xxαx(ζH2I)=0.
    $
    (2.13)

    For the solutions to (2.13) to be real,

    $ (ζH1I)24ζH2(ζH2I).
    $
    (2.14)

    In case $ I\geq\zeta_{H2} $, (2.14) is always fulfilled. In case $ I < \zeta_{H2} $, (2.14) is equivalent to

    $ I2+2rsβxeacxxαxI+rsβxeacxxαx(rsβxeacxxαx4esαx)0.
    $
    (2.15)

    Solving for $ I $ we get,

    $ IIH=γx(α2xζH34),
    $
    (2.16)

    with

    $ γx=4esrsβxeacxxα2xrsβxeacxxαx+2esrsβxeacxx>0.
    $
    (2.17)

    From Eqs (2.14) and (2.16) it follows that the solutions to Eq (2.13) are real for $ I\geq\zeta_{H2} $ or $ I_H\leq I < \zeta_{H2} $ in case $ I_H < \zeta_{H2} $.

    Whenever the solutions to (2.13) are real, they are given by

    $ ˉx0H±:=12escxxαx(IζH1±(ζH1I)24esαx(ζH2I)),
    $
    (2.18)

    which depends on the sign of the following five quantities,

    $ ζH1=2esαx(α2xζH32),
    $
    (2.19)
    $ IH=γx(α2xζH34),
    $
    (2.20)
    $ Δ12=ζH1ζH2=esαx(α2xζH3),
    $
    (2.21)
    $ ΔH1=ζH1IH=esαx+ζH3(α2xζH3), and 
    $
    (2.22)
    $ ΔH2=IHζH2=esαx(αx+ζH3)2(α2xζH3)20,
    $
    (2.23)

    where the last one immediately implies that the criteria for real solutions of Eq (2.13) is $ I\geq I_H $. If the solutions, $ \bar{x}_{0H\pm} $, are positive and real, then the formulas for the remaining variables easily follow from Eqs (2.4a–2.4f).

    To continue we first consider $ \bar{x}_{0H+} $ and afterwards $ \bar{x}_{0H-} $.

    For $ \alpha_x^2 \leq \frac{\zeta_{H3}}{4} $, it follows from Eqs (2.19)–(2.22) that $ \zeta_{H1} < 0 $, $ \zeta_{H1} < \zeta_{H2} $, $ I_H\leq 0 $, and $ \zeta_{H1} < I_H $. Thus, $ \bar{x}_{0H+} > 0 $ if and only if $ I > 0 $.

    For $ \frac{\zeta_{H3}}{4} < \alpha_x^2 \leq \frac{\zeta_{H3}}{2} $, it follows from Eqs (2.19)–(2.22) that $ \zeta_{H1}\leq 0 $, $ \zeta_{H1} < \zeta_{H2} $, $ I_H > 0 $, and $ \zeta_{H1} < I_H $. Thus, $ \bar{x}_{0H+} > 0 $ if and only if $ I > I_H $.

    For $ \frac{\zeta_{H3}}{2} < \alpha_x^2 \leq \zeta_{H3} $, it follows from Eqs (2.19)–(2.22) that $ \zeta_{H1} > 0 $, $ \zeta_{H1}\leq \zeta_{H2} $, $ I_H > 0 $, $ \zeta_{H1} < I_H $, and $ I_H\leq\zeta_{H2} $. Thus, $ \bar{x}_{0H+} > 0 $ if and only if $ I > I_H $.

    For $ \zeta_{H3} < \alpha_x^2 $ are $ \zeta_{H1} > 0 $, it follows from Eqs (2.19)–(2.23) that $ \zeta_{H1} > \zeta_{H2} $, $ I_H > 0 $, $ \zeta_{H1} > I_H $, and $ I_H\leq\zeta_{H2} $. Thus, $ \bar{x}_{0H+} > 0 $ if and only if $ I > \zeta_{H2} $.

    Similar, $ \bar{x}_{0H-} $ is real if and only if $ I \geq I_H $ and $ \zeta_{H1} < I < \zeta_{H2} $.

    For $ \alpha_x^2 \leq \frac{\zeta_{H3}}{4} $, it follows from Eqs (2.19) and (2.20) that $ \zeta_{H1} < 0 < \zeta_{H2} $, and $ I_H\leq 0 $. Thus, $ \bar{x}_{0H-} > 0 $ if and only if $ I < \zeta_{H2} $.

    For $ \frac{\zeta_{H3}}{4} < \alpha_x^2 \leq \frac{\zeta_{H3}}{2} $, it follows from Eqs (2.19), (2.20) and (2.23) that $ \zeta_{H1}\leq 0 < \zeta_{H2} $, $ I_H > 0 $, and $ I_H < \zeta_{H2} $. Thus, $ \bar{x}_{0H-} > 0 $ if and only if $ I_H\leq I < \zeta_{H2} $.

    For $ \frac{\zeta_{H3}}{2} < \alpha_x^2 \leq \zeta_{H3} $, it follows from Eqs (2.19)- (2.21) and (2.23) that $ 0 < \zeta_{H1} < \zeta_{H2} $, $ I_H > 0 $, and $ I_H < \zeta_{H2} $. Thus, $ \bar{x}_{0H-} > 0 $ if and only if $ I_H\leq I < \zeta_{H2} $.

    For $ \zeta_{H3} < \alpha_x^2 $, it follows from Eqs (2.20) and (2.21) that $ \zeta_{H1} > \zeta_{H2} $ and $ I_H > 0 $. Thus, $ \bar{x}_{0H-} > 0 $ if and only if $ \zeta_{H1} < I < \zeta_{H2} $, which is a contradiction.

    The conditions for the existence of the hematopoietic steady states are summarized in Table 1.

    Table 1.  Summarizing necessary and sufficient criteria for admissibility of $ E_H $. The first column conditions how $ \alpha_x $ is related to $ \zeta_{H3} $, the middle column shows the existence conditions for $ E_{H+} $ and the last column shows the existence conditions for $ E_{H\pm} $ explicitly in terms of $ I $.
    For Only $ E_{H+} $ if Both $ E_{H+} $ and $ E_{H-} $ if
    $ \alpha_x^2 < \frac{\zeta_{H3}}{4} $ $ I > \zeta_{H2} $ $ I \leq \zeta_{H2} $
    $ \frac{\zeta_{H3}}{4} < \alpha_x^2 < \zeta_{H3} $ $ I > \zeta_{H2} $ $ I_{H} \leq I \leq \zeta_{H2} $
    $ \zeta_{H3} < \alpha_x^2 $ $ I > \zeta_{H2} $ $ \emptyset $

     | Show Table
    DownLoad: CSV

    Malignant steady states may exist depending on therange of the parameters. As above we chose the inflammatory stimuli $ I $ as our leading parameter and make a complete analysis of possible malignant steady states. The analysis of the existence of the malignant steady states depends crucially on the following lumped parameters,

    $ IH=2esrsβyeacyyrsβyeacyyαy,
    $
    (2.24)
    $ ζL1=2esαyrsβyeacyyαy,
    $
    (2.25)
    $ ζL2=esαy,
    $
    (2.26)
    $ ζL3=rsβyeseacyy,
    $
    (2.27)

    the last two being positive.

    Proposition 3. Two malignant steady states $ E_{L\pm} $ may exist in the following cases,

    If $ \alpha_y^2 \leq \frac{\zeta_{L3}}{4} $ then $ E_{L+} $ exists if and only if $ I > 0 $.

    If $ \frac{\zeta_{L3}}{4} < \alpha_y^2 \leq \zeta_{L3} $ then $ E_{L+} $ exists if and only if $ I \geq I_{L} $.

    If $ \zeta_{L3} < \alpha_y^2 $ then $ E_{L+} $ exists if and only if $ I > \zeta_{L2} $.

    If $ \alpha_y^2 \leq \frac{\zeta_{L3}}{4} $ then $ E_{L-} $ exists if and only if $ I \leq \zeta_{L2} $.

    If $ \frac{\zeta_{L3}}{4} < \alpha_y^2 \leq \zeta_{L3} $ then $ E_{L-} $ exists if and only if $ I_{L} \leq I \leq \zeta_{L2} $.

    If $ \zeta_{L3} < \alpha_y^2 $ then $ E_{L-} $ does not exist.

    In case of existence, $ E_{L+} = (0, 0, \bar{y}_{0L+}, \bar{y}_{1L+}, \bar{a}_{L+}, \bar{s}_{L+}) $ is given by $ \bar{y}_{0L+} = \frac{1}{2 e_s c_{yy}\alpha_y} \left(I-\zeta_{L1} + \sqrt{(\zeta_{L1}-I)^2-4 e_s \alpha_y(\zeta_{L2}-I)}\right) $, $ \bar{s}_{L+} = \alpha_y (1+c_{yy} \bar{y}_{0L+}) $, $ \bar{a}_{L+} = \frac{\beta_y \bar{y}_{0L+}}{e_a \bar{s}_{L+}} $, and $ \bar{y}_{1L+} = \frac{a_x A_x \bar{y}_{0L+}}{d_{y1}} $ whereas $ E_{L-} = (0, 0, \bar{y}_{0L-}, \bar{y}_{0L-}, \bar{a}_{L-}, \bar{s}_{L-}) $ is given by $ \bar{y}_{0L-} = \frac{1}{2 e_s c_{yy}\alpha_y} \left(I-\zeta_{L1} - \sqrt{(\zeta_{L1}-I)^2-4 e_s \alpha_y(\zeta_{L2}-I)}\right) $, $ \bar{s}_{L-} = \alpha_y (1+c_{yy} \bar{y}_{0L-}) $, $ \bar{a}_{L-} = \frac{\beta_y \bar{y}_{0L-}}{e_a \bar{s}_{L-}} $, and $ \bar{y}_{1L-} = \frac{a_x A_x \bar{y}_{0L-}}{d_{y1}} $.

    Proof. Due to symmetry in indices $ x $ and $ y $, the proof for the malignant case is equivalent to that for the hematopoietic case except index $ H $ has to be substituted by $ L $.

    The result is summarized in Table 2.

    Table 2.  Summarizing necessary and sufficient criteria for admissibility of $ E_L $. The first column conditions how $ \alpha_y $ is related to $ \zeta_{L3} $, the middle column shows the existence conditions for $ E_{L+} $ and the last column shows the existence conditions for $ E_{L\pm} $ explicitly formulated in terms of $ I $.
    For Only $ E_{L+} $ if Both $ E_{L+} $ and $ E_{L-} $ if
    $ \alpha_y^2 < \frac{\zeta_{L3}}{4} $ $ I > \zeta_{L2} $ $ I \leq \zeta_{L2} $
    $ \frac{\zeta_{L3}}{4} < \alpha_y^2 < \zeta_{L3} $ $ I > \zeta_{L2} $ $ I_{L} \leq I \leq \zeta_{L2} $
    $ \zeta_{L3} < \alpha_y^2 $ $ I > \zeta_{L2} $ $ \emptyset $

     | Show Table
    DownLoad: CSV

    The existence of a co-existing steady state

    $ E_C = (\bar{x}_{0C}, \bar{x}_{1C}, \bar{y}_{0C}, \bar{y}_{1C}, \bar{a}_{C}, \bar{s}_{C}) \, , $

    is far more cumbersome to deal with, since a wealth of sub-cases may arrive depending on various inequality-relations between the parameters. To avoid many tedious but straight forward calculations we limit ourself to the non-degenerate cases where $ \zeta_{C1} = \alpha_yc_{yx}- \alpha_xc_{xx} \neq 0 $ and $ \zeta_{C2} = \alpha_yc_{yy}- \alpha_xc_{xy} \neq 0 $.

    From Eqs (2.4a and 2.4b), a linear relation between $ \bar{x}_0 $ and $ \bar{y}_0 $ directly follows,

    $ ζC1ˉx0C+ζC2ˉy0CζC3=0,
    $
    (2.28)

    where $ \zeta_{C3} = \alpha_x-\alpha_y $. Thus, for the non-degenerate cases,

    $ ˉy0C=ζC1ζC2(ζC3ζC1ˉx0C),
    $
    (2.29)

    which geometrically corresponds to a straight line through $ \left(0, \frac{\zeta_{C3}}{\zeta_{C2}}\right) $ and $ \left(\frac{\zeta_{C3}}{\zeta_{C1}}, 0\right) $. Hence, two generic cases arrive, for $ \left(0, \frac{\zeta_{C1}}{\zeta_{C2}}\right) $ corresponding to positive slope, $ \frac{\zeta_{C1}}{\zeta_{C2}} < 0 $ corresponding to negative slope, $ \frac{\zeta_{C1}}{\zeta_{C2}} > 0 $. The first case defines a half line in the positive octahedron and in this case $ \bar{x}_{0C}\in(\max\{0, \frac{\zeta_{C3}}{\zeta_{C1}}\}; \infty) $ and $ \bar{y}_{0C}\in(\max\{0, \frac{\zeta_{C3}}{\zeta_{C2}}\}; \infty) $. The second case corresponds to either no admissible solution (if and only if $ \frac{\zeta_{C3}}{\zeta_{C2}} < 0 $ and $ \frac{\zeta_{C3}}{\zeta_{C1}} < 0 $) or a line segment in the positive octahedron which requires that $ \frac{\zeta_{C3}}{\zeta_{C2}} > 0 $ and $ \frac{\zeta_{C3}}{\zeta_{C1}} > 0 $ and in that case are $ \bar{x}_{0C}\in(0, \frac{\zeta_{C3}}{\zeta_{C1}}) $ and $ \bar{y}_{0C}\in(0, \frac{\zeta_{C3}}{\zeta_{C2}}) $. From Eq (2.4a) and (2.29),

    $ ˉsC=m1ˉx0C+m0,
    $
    (2.30)

    with $ m_0 = \alpha_x (c_{xy}\frac{\zeta_{C3}}{\zeta_{C2}}+1) $ and $ m_1 = \alpha_x (c_{xx}-c_{xy}\frac{\zeta_{C1}}{\zeta_{C2}}) $. Before continuing, it is emphasized that $ \zeta_1 $, $ \zeta_2 $, $ \zeta_3 $, $ m_0 $, and $ m_1 $ all are independent of $ I $ but may be positive, negative or in case of $ m_0 $ and $ m_1 $ zero. From Eq (2.7) it follows that a real and positive $ \bar{s} $ exist for $ (\bar{x}_{0C}, \bar{y}_{0C})\in \mathbb{R}_+ \times \mathbb{R}_+ $,

    $ ˉsC=I2es(1+1+ζ0I2(βxˉx0C+βyˉy0C))
    $
    (2.31)

    where $ \zeta_0 = \frac{4 r_s e_s}{e_a} > 0 $. Similarly, a negative real root exists. Substituting (2.29) into (2.31) give,

    $ ˉsC=I2es+(I2es)2+ζ0βyζC34e2sζC2+ζ04e2s(βxβyζC3ζC2)ˉx0C.
    $
    (2.32)

    Combining Eq (2.30) and (2.32) results in,

    $ n0I+n1ˉx0C=I2+n2+n3ˉx0C,
    $
    (2.33)

    where $ n_0 = 2e_sm_0 $, $ n_1 = 2e_sm_1 $, $ n_2 = \frac{\zeta_0 \beta_y \zeta_{C3}}{\zeta_{C2}} $ and $ n_3 = \zeta_0 \left(\beta_x-\beta_y\frac{\zeta_{C1}}{\zeta_{C2}}\right) $.

    Note that Eq (2.33) has no real solution if either of $ f(x) = n_0-I+n_1 x $ and $ g(x) = I^2+n_2+n_3 x $ are negative. Thus, if both $ f(x) $ and $ g(x) $ are positive, Eq (2.33) is equivalent to,

    $ n21x2+(2n1(n0I)n3)x+(n20n22n0I)=0,
    $
    (2.34)

    which may have up to two real positive solutions. Hence, there can be at most two coexistence steady states. More specifically,

    $ x0C+=2n1(n0I)n32n21+(2n1(n0I)n32n21)2n20n22n0In1,
    $
    (2.35)

    is positive if and only if $ f(x_{0C+}) > 0 $, $ g(x_{0C+}) > 0 $, and

    $ n20n22n0In1<0 or 2n1(n0I)n3n21<0.
    $
    (2.36)

    Similar,

    $ x0C=2n1(n0I)n32n21(2n1(n0I)n32n21)2n20n22n0In1,
    $
    (2.37)

    is positive if and only if $ f(x_{0C-}) > 0 $, $ g(x_{0C-}) > 0 $, and

    $ 2n1(n0I)n32n21>n20n22n0In1>0 and 2n1(n0I)n32n21<0.
    $
    (2.38)

    Note, some possibilities of equality signs in the inequalities are left out for simplification reasons. Equality may occur on a set of measure zero which is unlikely for a noisy biological system and including these possibilities makes the analysis much more messy. For practical purposes one may first calculate the two (possibly complex) roots $ x $ of Eq (2.34) and afterwards examine whether these are real and positive, whether $ f(x) > 0 $ and $ g(x) > 0 $, and whether the corresponding $ \bar{y}_{0C} $ calculated from Eq (2.29) is positive, thus the remaining component of $ E_{C} $ will be positive too and the steady state admissible.

    Continuing analytically is possible but becomes somehow cumbersome and instead we point out that for any choice of parameter values, there can be at most two coexistence steady states, their existence and value depending on the admissibility of $ x_{0C+} $ (Eq (2.35)) and $ x_{0C-} $ (Eq (2.37)).

    In this section we analytically and numerically examine the stability properties of the various admissible steady states of Eq (2.1) in terms of selected parameters.

    The Jacobian of the trivial steady states $ E_0 $ is a triangular matrix and four of the six eigenvalues, $ -d_{x1}, -d_{y1}, -e_s $ and $ \frac{-I e_a}{e_s} $, are negative but the two, $ \frac{r_x}{e_s} \left(I-e_s \alpha_x\right) $ and $ \frac{r_y}{e_s} \left(I-e_s \alpha_y\right) $, may be positive, negative, zero. Thus, by the Hartman-Grobman Theorem [34]

    Lemma 1. $ E_0 $ is asymptotically stable if $ I < e_s \min \{\alpha_x, \alpha_y\} $, whereas it is unstable if $ I > e_s \min \{\alpha_x, \alpha_y\} $.

    At $ E_{H\pm} $ the Jacobian for the hematopoietic states can be calculated (see Supplementary) and the resulting sixth order characteristic equation shows that $ E_{H\pm} $ are stable for

    $ ˉsH<αy(1+cyxˉx0H).
    $
    (3.1)

    However, this is not the generic case, since $ \alpha_y < \alpha_x $ (and $ c_{yx} \leq c_{xx} $), which contradicts $ \bar{s}_H = \alpha_x (1+c_{xx}\bar{x}_{0H}) $. Intensive numerical investigations shows that $ E_{H\pm} $ are unstable.

    The stability of $ E_L $ is similar to that for the hematopoietic steady state except that it is stable if

    $ ˉsL<αx(1+cxyˉy0L),
    $
    (3.2)

    which is fulfilled in the generic case, since $ \alpha_x < \alpha_y $ (and $ c_{xy} \leq c_{yy} $). This follows from $ \bar{s}_L = \alpha_y (1+c_{yy}\bar{y}_{0L}) $. The Jacobian may be found in supplementary.

    Lastly, consider the co-existing steady state. The Jacobian at $ E_{C} $ may be found in supplementary. However, it is hard to prove any result analytically and we therefore do the stability investigation numerically the in next section.

    In this section, we focus on numerical results. The default values of parameters used in Figure 2 are given in Table 3. The values are the same as given in [18].

    Figure 2.  Admissibility and stability of the steady states depending on the parameters $ I $ and $ \mathcal{C} $ for different values of $ \mathcal{R} $. Crossing a solid curve implies a change in which type of stable steady state exists i.e. trivial, malignant, hematopoietic or coexistence. Crossing a dotted curves implies the same steady state is stable in both regions but the number of steady states is changed. The stable steady states are written as subscript of $ E $ and unstable steady states are written as superscript of $ E $.
    Table 3.  Default parameter values and their lumped counterpart.
    Parameter Value Unit Parameter Value Unit
    $ r_x $ $ 8.7\cdot 10^{-4} $ day$ ^{-1} $ $ r_y $ $ 1.3\cdot 10^{-3} $ day$ ^{-1} $
    $ a_x $ $ 1.1\cdot 10^{-5} $ day$ ^{-1} $ $ a_y $ $ 1.1\cdot 10^{-5} $ day$ ^{-1} $
    $ A_x $ $ 4.7\cdot 10^{13} $ - $ A_y $ $ 4.7\cdot 10^{13} $ -
    $ d_{x_0} $ $ 2\cdot 10^{-3} $ day$ ^{-1} $ $ d_{y_0} $ $ 2\cdot 10^{-3} $ day$ ^{-1} $
    $ d_{x_1} $ 129 day$ ^{-1} $ $ d_{y_1} $ 129 day$ ^{-1} $
    $ c_{xx} $ $ 5.6\cdot 10^{-5} $ - $ c_{yx} $ $ 5.2\cdot 10^{-5} $ -
    $ c_{xy} $ $ 5.4\cdot 10^{-5} $ - $ c_{yy} $ $ 5.0\cdot 10^{-5} $ -
    $ e_s $ 2 day$ ^{-1} $ $ r_s $ $ 3\cdot 10^{-4} $ day$ ^{-1} $
    $ e_a $ $ 2\cdot 10^{9} $ day$ ^{-1} $ $ I $ $ 7 $ day
    $ \alpha_x $ $ 2.31 $ - $ \alpha_y $ $ 1.54 $ -
    $ \beta_x $ $ 5.17 \cdot 10^{8} $ - $ \beta_y $ $ 5.17 \cdot 10^{8} $ -
    $ \zeta_0 $ $ 1.2\cdot 10^{-12} $ - $ \zeta_{C1} $ $ -4.9\cdot 10^{-5} $ -
    $ \zeta_{C2} $ $ 7.4146\cdot 10^{-4} $ - $ \zeta_{C3} $ $ 0.7646 $ -
    $ n_0 $ $ 9.76 $ - $ n_1 $ $ - 0.51 $ -
    $ n_2 $ $ 0.64 $ - $ n_3 $ $ 6.61 \cdot 10^{-4} $ -
    $ \zeta_{H1} $ $ 8.65 $ - $ \zeta_{H2} $ $ 4.62 $ -
    $ \zeta_{L1} $ $ 5.18 $ - $ \zeta_{L2} $ $ 3.09 $ -
    $ \zeta_{H3} $ $ 0.69 $ - $ \zeta_{L3} $ $ 0.7646 $ -

     | Show Table
    DownLoad: CSV

    The model has been investigated for various choices of parameter values. In Figure 2, clusters of five important parameters, $ \mathcal{C} = \frac{c_{xx}}{c_{yy}} $, $ \mathcal{R} = \frac{\zeta_{H2}}{\zeta_{L2}} = \frac{\alpha_x}{\alpha_y} $ and $ I $ are considered to investigate the number of steady states and their stability. In the default case $ \mathcal{R} > 1 $ (Figure 2a), a trivial steady state always exists, and for low inflammation, i.e., $ I < \zeta_{L2} $ it is stable otherwise it is unstable. For $ I > \zeta_{L2} $, a purely malignant steady state becomes admissible. For values of $ I $ where the trivial and the malignant steady states are admissible, the malignant steady state is stable whereas the trivial steady state is unstable. An unstable hematopoietic steady state becomes admissible as $ I $ becomes larger than the threshold value $ \zeta_{H2} $, and increasing $ I $ further causes emergence of a stable co-existing steady state while the malignant steady state becomes unstable. Thus, for $ I > \zeta_{H2} $ and $ \mathcal{C} $ sufficiently small, four steady states appear namely the trivial, the hematopoietic, the malignant and the co-existing steady states where the co-existing steady state is stable and the rest are unstable. This illustrates that the co-existing steady state depends on $ I $, $ \mathcal{C} $ and $ \mathcal{R} $. Increasing $ \mathcal{C} $ from a small, initial value makes the co-existing steady state vanish and the malignant steady state becomes stable whereas the trivial and the hematopoietic steady states remain unstable. Secondly, consider the second case where $ \mathcal{R} = 1 $ implying that $ \zeta_{H2} = \zeta_{L2} $ (Figure 2b). Increasing $ I $ across this value generates an unstable hematopoietic steady state and a malignant steady state simultaneously. For $ \mathcal{C} < 1 $ the malignant steady state is unstable, and a stable coexistence steady state is created as $ I $ increase past $ \zeta_{H2} $. For $ \mathcal{C} > 1 $ no coexistence steady state is created, instead the malignant steady state is stable. Hence, for $ \mathcal{R} = 1 $, decreasing $ \mathcal{C} $ may change the topology from a stable malignant steady state to a stable coexistence steady state i.e. improving the prognosis from disease escape to disease equilibrium. The stable co-existing steady state bifurcates from the trivial steady state and remains stable until $ \mathcal{C} = 1 $. As $ \mathcal{C} $ exceeds $ 1 $, the co-existing steady state disappears, the malignant steady state becomes stable and the trivial and the hematopoietic steady state become unstable.

    In the remaining panels, $ \mathcal{R} < 1 $, which implies that a stable hematopoietic steady state is created as the first transition to appear when increasing $ I $ from low values past the threshold value $ \zeta_{H2} $. Simultaneously, the trivial steady state becomes unstable. In Figure 2c where $ \mathcal{R} = 0.97 $ the hematopoietic steady state remains stable for low values of $ \mathcal{C} $ until $ I $ passes a threshold value where a stable coexistence steady state is created leaving the hematopoietic steady state unstable.

    For larger values of $ \mathcal{C} $ there is no coexistence steady state. Instead, as $ I $ is increased, a region of bistability appears with a stable hematopoietic steady state and a stable malignant steady state. Increasing $ I $ further the hematopoietic steady state becomes unstable. Hence, to reduce disease load, in the case of $ \mathcal{R} < 1 $, and large values of $ \mathcal{C} $ and $ I $, it may be optimal treatment to reduce the $ \mathcal{C} $ value prior to reducing the inflammatory level to avoid being stuck in the bassin of attraction of the malignant steady state.

    In Figure 2d where $ \mathcal{R} = 0.93 $, the coexistence steady state no longer appears, the region of bistability has shrunk and a hematopoietic stable steady state is more dominant.

    In Figure 2e and f, $ \mathcal{R} $ is decreased to $ 0.77 $ and $ 0.5 $ respectively, and the bistability region is no longer visible. For $ I > \zeta_{H2} $ a hematopoietic steady state is the only stable steady state. Figure 2 indicates that reducing $ \mathcal{C} $ and $ \mathcal{R} $ should be targets of intervention. A reduction of $ I $ may improve prognosis as well, for example for parameter values as in 2c.

    A mechanism-based model published in [5] - the Cancitis model - describing the interaction of the hematopoietic cells, malignant cells and inflammation is analysed here. A thorough mathematical investigation of the model is presented in this paper which did not appear previously. We conducted an analytical analysis of the steady states and showed that four kinds of steady states may exist i.e. trivial, hematopoietic, malignant and co-existing steady states. We characterized the stability of each of these steady states and identified transitions conditions in the number of steady states and in their stability. Trivial, hematopoietic, malignant and coexistence steady states all appear for some parameter values. The steady states are highly relevant as all trajectories appear to approach a steady state after some time - see Figure 3. The case of bistability is visualized in the bottom right panel of Figure 3, with the basin of attraction shown in the $ (x_0, y_0) $-plane using initial condition $ (x_1, y_1, a, s) = (4\times 10^{11}, 4\times 10^{11}, 600, 2) $. The initial conditions for $ x_0 $ and $ y_0 $ are varied in a range $ 1-10^{5} $. The malignant steady state has a large bassin of attraction (region (i)), while region (ii) marks the bassin of attraction for the hematopoietic steady state.

    Figure 3.  The first three panels illustrate that when a unique, stable steady state exists, it is globally attracting (based on a numerical argument). $ U(t) $ denotes the solution of the six-dimensional model 2.1. In the top left panel, $ \frac{||U(t)-E_{H}||}{||U(0)-E_{H}||} $ is plotted against time for three different initial conditions. It corresponds to the region where $ E_H $ is stable with $ \mathcal{C} = 0.8 $, $ \mathcal{R} = 0.97 $ and $ I = 6 $. $ \frac{||U(t)-E_{H}||}{||U(0)-E_{H}||} $ tending to zero for large time implies that $ U(t) $ is close to $ E_H $ for large time. The top right panel shows the stability of $ E_L $ with $ \mathcal{C} = 0.2 $, $ \mathcal{R} = 1.5 $ and $ I = 4 $. The bottom left panel shows the stability of $ E_C $ with $ \mathcal{C} = 0.1 $, $ \mathcal{R} = 1.5 $ and $ I = 7 $. The bottom right panel corresponds to bi-stability of $ E_H $ and $ E_L $ with $ \mathcal{C} = 1.4 $, $ \mathcal{R} = 0.97 $. The solution to the 6D model is projected onto the $ x_0 $ and $ y_0 $ plane. Region $ (i) $ denotes the set of initial conditions with trajectories converging to $ E_L $ whereas region $ (ii) $ denotes that trajectories converge to $ E_H $. Black circles show four steady states, $ E_0 $, $ E_H $, $ E_L $ and $ E_C $, where filled circle shows stable steady states and empty circle shows unstable steady states.

    The intuitive interpretation in most bio-medical literature attributes the main cause for cancer development to the frequency of stem cell division. Another main cause is the regulatory feedback that allows stem cells residing in niche to further divide into blood cell required in blood stream. Our investigation is in agreement with this perception and quantifies this intuitive concept. Furthermore, it shows that stem cell population is important to target in treatment to prevent disease progression.

    In [14] and [15] a model without immune interaction is presented. The authors discuss a fraction similar to $ \mathcal{R} $ and show that it is important for the dynamics of the system. It has been shown [15] that the leukemic cell load can be temporarily reduced if the growth of HSC is larger than that of leukemic cells for cytokine-dependent AML.

    It is generally assumed that $ c_{yy} \leq c_{xx} $ since malignant cells might be less sensitive to environmental crowding [22] and [24]. The ratio $ \mathcal{C} $ of inhibition of the hematopoietic relative to malignant cells is one of several important prognostic markers. For large values of $ I $, bi-stable and mono-stable regions depend upon $ \mathcal{C} $. It can be observed in Figure 2 that for small values of $ \mathcal{C} $, i.e., $ c_{yy} \geq c_{xx} $, either the hematopoietic steady state is stable or the co-existing steady state is stable which can be interpreted as a good prognosis. However, large values of $ \mathcal{C} $ may lead to a worse situation, e.g. in one case, the malignant steady state is stable or there exists bi-stability of the hematopoietic and the malignant steady states (see Figure 2c). In addition to the ratio of inhibitive niche feedback, the ratio $ \mathcal{R} $ is also important to consider, since it determines how robust the hematopoietic condition may be and how disastrously a potential blood cancer disease will develop. Thus for $ \mathcal{R} > 1 $ we have a more serious situation than for $ \mathcal{R} < 1 $ showing that if this reproduction ratio exceeds the threshold $ \mathcal{R}_0 = 1 $, it is more disastrous than if it is below $ \mathcal{R}_0 $.

    The $ JAK2 $V617F allele burden is expected to increase due to the expansion of malignant cells. The $ JAK2 $V617F allele burden is interpreted as the ratio of malignant cells to the total number of mature cells. The model predicted $ JAK2 $V617F allele burden is shown in Figure 4 for the region where $ E_C $ is stable. Perturbation of a parameter may improve or impair prognosis when the coexistence point is the stable attractor. The top panel of Figure 4, shows that decreasing $ \mathcal{C} $ and $ \mathcal{R} $ improve prognosis by lowering the allele burden. Contrarily, increasing $ I $, causes a decay in allele burden. This suggests that inflammatory inhibitors could counteract treatments in this case. In other cases, increasing $ I $ typically leads to a worse prognosis, considering Figure 2.

    Figure 4.  Allele burden (the ratio of $ \bar y_{1c} $ to the total number of $ \bar x_{1c} $ and $ \bar y_{1c} $) at the steady state for the region where the co-existing steady state is stable. On the top, left and right panels show that by increasing $ \mathcal{C} $ and $ \mathcal{R} $, allele burden also increases. On the contrary, increasing $ I $ reduces the allele burden. In the top panel $ \mathcal{R} = 1.5 $ and $ I = 7 $, in the top right, $ \mathcal{C} = 0.1 $ and $ I = 7 $ and in the bottom panel, $ \mathcal{R} = 1.5 $ and $ \mathcal{C} = 0.1 $.

    The model presented here may inform clinical practice to make group specific treatment protocols with particular focus on the inflammatory components which may accelerate or dampen the disease progression. Interventions should address decreasing $ \mathcal{C} $ and $ \mathcal{R} $ and potentially $ I $ but the latter depends on the remaining parameter values as adverse effects may be observed.

    No conflict of interest.

    Stability analysis of Steady states:

    At $ E_{H\pm} $ the Jacobian of the purely hematopoietic steady state becomes,

    $ JEH=[a110a1300a16a21a22000000a3300000a43a4400a51a52a53a54a55a560000a65a66]
    $
    (6.1)

    where

    $ a_{11} = r_x \left(\frac{\bar{s}_{H}}{(1+c_{xx} \bar{x}_{0H})^2}-\alpha_x\right) $,

    $ a_{13} = -\frac{r_x c_{xy} \bar{s}_{H} \bar{x}_{0H}}{(1+c_{xx} \bar{x}_{0H})^2} $,

    $ a_{16} = \frac{r_x \bar{x}_{0H}}{(1+c_{xx} \bar{x}_{0H})} $,

    $ a_{21} = a_x A_x $,

    $ a_{22} = -d_{x1} $,

    $ a_{33} = r_y \left(\frac{\bar{s}_{H}}{1+c_{yx} \bar{x}_{0H}}-\alpha_y\right) $,

    $ a_{43} = a_y A_y $,

    $ a_{44} = -d_{y1} $,

    $ a_{51} = d_{x0} $,

    $ a_{52} = d_{x1} $,

    $ a_{53} = d_{y0} $,

    $ a_{54} = d_{y1} $,

    $ a_{55} = -e_a \bar{s}_{H} $,

    $ a_{56} = -e_a \bar{a}_{H} $,

    $ a_{65} = r_s $,

    $ a_{66} = -e_s $,

    and rest of the elements of $ J_{E_H} $ are zero.

    At $ E_{L\pm} $ the Jacobian of the purely malignant steady state.

    $ JEL=[a1100000a21a220000a310a3300a3600a43a4400a51a52a53a54a55a560000a65a66]
    $
    (6.2)

    where

    $ a_{11} = r_x\left(\frac{ \bar{s}_{L}}{1+c_{xy}\bar{y}_{0L}}-\alpha_x\right) $,

    $ a_{21} = a_x A_x $,

    $ a_{22} = -d_{x1} $,

    $ a_{31} = -\frac{r_y c_{yx}\bar{s}_{L} \bar{y}_{0L}}{(1+c_{yy} \bar{y}_{0L})^2} $,

    $ a_{33} = r_y \left(\frac{\bar{s}_{L}}{(1+c_{yy}\bar{y}_{0L})^2}-\alpha_y\right) $,

    $ a_{36} = \frac{r_y \bar{y}_{0L}}{1+c_{yy}\bar{y}_{0L}} $.

    $ a_{43} = a_y A_y $.

    $ a_{44} = -d_{y1} $.

    $ a_{51} = d_{x0} $.

    $ a_{52} = d_{x1} $.

    $ a_{53} = d_{y0} $.

    $ a_{54} = d_{y1} $.

    $ a_{55} = -e_a \bar{s}_{L} $.

    $ a_{56} = -e_a \bar{a}_{L} $.

    $ a_{65} = r_s $.

    $ a_{66} = -e_s $

    and rest of the elements of array are zero.

    At $ E_{C\pm} $ the Jacobian of the co-existing steady state becomes,

    $ JEC=[a110a1300a16a21a220000a310a3300a3600a43a4400a51a52a53a54a55a560000a65a66]
    $
    (6.3)

    where

    $ a_{11} = r_x \left(\frac{\bar{s}_C}{(1+c_{xx}\bar{x}_{0C}+c_{xy} \bar{y}_{0C})^2}-\alpha_x \right) $,

    $ a_{13} = -\frac{r_x c_{xy} \bar{s}_C \bar{x}_{0C}}{(1+c_{xx}\bar{x}_{0C}+c_{xy}\bar{y}_{0C})^2} $,

    $ a_{16} = \frac{r_x \bar{x}_{0C}}{(1+c_{xx}\bar{x}_{0C}+c_{xy} \bar{y}_{0C})} $,

    $ a_{21} = a_x A_x $,

    $ a_{22} = -d_{x1} $,

    $ a_{31} = -\frac{r_y c_{yx} \bar{s}_C \bar{y}_{0C}}{(1+c_{yx}\bar{x}_{0C}+c_{yy}\bar{y}_{0C})^2} $,

    $ a_{33} = r_y \left(\frac{\bar{s}_C}{(1+c_{yx}\bar{x}_{0C}+c_{yy} \bar{y}_{0C})^2}-\alpha_y \right) $,

    $ a_{36} = \frac{r_y \bar{y}_{0C}}{(1+c_{yx}\bar{x}_{0C}+c_{yy} \bar{y}_{0C})} $,

    $ a_{43} = a_y A_y $,

    $ a_{44} = -d_{y1} $,

    $ a_{51} = d_{x0} $,

    $ a_{52} = d_{x1} $,

    $ a_{53} = d_{y0} $,

    $ a_{54} = d_{y1} $,

    $ a_{55} = -e_a \bar{s}_C $,

    $ a_{56} = -e_a \bar{a}_C $,

    $ a_{65} = r_s $,

    $ a_{66} = -e_s $

    and rest of the elements of the $ J_{E_C} $ are zero.



    [1]

    MTD, NCI Dictionary of Cancer Terms, https://www.cancer.gov/publications/dictionaries/cancer-terms/def/mtd, accessed 08/18/18.

    [2] Metronomic scheduling of anticancer treatment: The next generation of multitarget therapy?. Future Oncology (2011) 7: 385-394.
    [3] Designing proliferating cell population models with functional targets for control by anti-cancer drugs. Discr. and Cont. Dyn. Syst., Series B (2013) 18: 865-889.
    [4]

    F. Billy, J. Clairambault and O. Fercoq, Optimisation of Cancer Drug Treatments Using Cell Population Dynamics, in: Mathematical Methods and Models in Biomedicine, (U. Ledzewicz, H. Schättler, A. Friedman and E. Kashdan, Eds.), Springer, New York, 2013, 265–309.

    [5] Concentration phenomena in some non-local equation. J. Discrete and Continuous Dynamical Systems, Series B (2017) 22: 763-781.
    [6]

    B. Bonnard and M. Chyba, Singular Trajectories and their Role in Control Theory, Mathématiques & Applications, vol. 40, Springer Verlag, Paris, 2003.

    [7]

    A. Bressan and B. Piccoli, Introduction to the Mathematical Theory of Control, American Institute of Mathematical Sciences, 2007.

    [8]

    M. Delitalia and T. Lorenzi, Formations of evolutionary patterns in cancer dynamics, in: Pattern Formation in Morphogenesis: Problems and Mathematical Issues, (V. Capasso et al., Eds.), Springer Proceedings in Mathematics, 15 (2013), 179–190.

    [9] Recognition and learning in a mathematical model for immune response against cancer. Discr. and Cont. Dyn. Syst., Series B (2013) 18: 891-914.
    [10]

    M. Delitalia and T. Lorenzi, Mathematical modelling of cancer under target therapeutic actions: Selection, mutation and drug resistance, in: Managing Complexity, Reducing Perplexity in Biological Systems, (M. Delitala and G. Ajmone Marsan Eds.), Springer Proceedings in Mathematics & Statistics, 2014, 81–99.

    [11] Cancer immunoediting: From immunosurveillance to tumor escape. Nat. Immunol. (2002) 3: 991-998.
    [12] Cancer epigenetics: Tumor Heterogeneity, Plasticity of Stem-like States, and Drug Resistance. Molecular Cell (2014) 54: 716-727.
    [13]

    M. Eisen, Mathematical Models in Cell Biology and Cancer Chemotherapy, Lecture Notes in Biomathematics, Vol. 30, Springer Verlag, Berlin, 1979.

    [14] A change of strategy in the war on cancer. Nature (2009) 459: 508-509.
    [15] Adaptive therapy. Cancer Research (2009) 69: 4894-4903.
    [16] Drug resistance in cancer: A perspective. Cancer and Metastasis Review (2001) 20: 63-68.
    [17] A model for resistance of tumor cells to cancer chemotherapeutic agents. Mathematical Biosciences (1983) 65: 291-307.
    [18] The penetration of anticancer drugs through tumor tissue as a function of cellular adhesion and packing density of tumor cells. Cancer Research (2006) 66: 1033-1039.
    [19] The impact of cell density and mutations in a model of multidrug resistance in solid tumors. Bull. Math. Biol. (2014) 74: 627-653.
    [20] Cell resensitization during protracted dosing of heterogeneous cell populations. Radiation Research (1998) 150: 681-687.
    [21] Minimizing long-term burden: the logic for metronomic chemotherapeutic dosing and its angiogenic basis. J. of Theoretical Biology (2003) 220: 545-554.
    [22] Less is more, regularly: Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J. Clinical Investigations (2000) 105: 1045-1047.
    [23] An optimal control problem related to leukemia chemotherapy. Scientific Bulletins of the Silesian Technical University (1983) 65: 120-130.
    [24] The role of cell density and intratumoral heterogeneity in multidrug resistance. Cancer Research (2013) 73: 7168-7175.
    [25] Optimal bang-bang controls for a 2-compartment model in cancer chemotherapy. J. of Optimization Theory and Applications - JOTA (2002) 114: 609-637.
    [26] Analysis of a cell-cycle specific model for cancer chemotherapy. J. of Biological Systems (2002) 10: 183-206.
    [27] Drug resistance in cancer chemotherapy as an optimal control problem. Discrete and Continuous Dynamical Systems, Series B (2006) 6: 129-150.
    [28]

    U. Ledzewicz and H. Schättler, Tumor microenvironment and anticancer therapies: An optimal control approach, in: Mathematical Oncolgy 2013, (A. d'Onofrio and A. Gandolfi, Eds.), Birkhäuser, New York, 2013, 295–334.

    [29] A $3$-compartment model for chemotherapy of heterogeneous tumor populations. Acta Applicandae Matematicae (2015) 135: 191-207.
    [30] Optimal controls for a mathematical model of tumor-immune interactions under targeted chemotherapy with immune boost. Discrete and Continuous Dynamical Systems, Series B (2013) 18: 1031-1051.
    [31] On optimal chemotherapy for heterogeneous tumors. J. of Biological Systems (2014) 22: 177-197.
    [32] A review of optimal chemotherapy protocols: From MTD towards metronomic therapy. Math. Model. Nat. Phenom. (2014) 9: 131-152.
    [33]

    U. Ledzewicz and H. Schättler, Optimizing chemotherapeutic anti-cancer treatment and the tumor microenvironment: an analysis of mathematical models, in: Systems Biology of Tumor Microenvironment, Advances in Experimental Medicine and Biology Vol. 936, (K.A. Rejniak (ed.)), 2016, 209–223.

    [34] Population adaptive evolution, chemotherapeutic resistance and multiple anti-cancer therapies. ESAIM: Mathematical Modelling and Numerical Analysis (2013) 47: 377-399.
    [35] Effects of space structure and combination therapies on phenotypic heterogeneity and drug resistance in solid tumors. Bull. Math. Biol. (2015) 77: 1-22.
    [36] Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treatment Reports (1977) 61: 1307-1317.
    [37] The Norton-Simon hypothesis revisited. Cancer Treatment Reports (1986) 70: 41-61.
    [38]

    B. Perthame, Transport Equations in Biology, Birkhäuser, Basel, Switzerland, 2007.

    [39] A multi-targeted, metronomic and maximum tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J. of Clinical Oncology (2005) 23: 939-952.
    [40]

    L. S. Pontryagin, V. G. Boltyanskii, R. V. Gamkrelidze and E. F. Mishchenko, The Mathematical Theory of Optimal Processes, Macmillan, New York, 1964.

    [41]

    C. Pouchol, J. Clairambault, A. Lorz and E. Trélat, Asymptotic analysis and optimal control of integro-differential system modelling healtyh and ccells exposed to chemotherapy, J. de Mathématiques Pures et Appliquées, 2017; arXiv: 1612.04698 [math.OC]

    [42]

    E. Ramos, C. Nespoli and P. Ramos, Feedback optimal control for mathematical models for cancer treatment, Preprint, 2018.

    [43]

    H. Schättler and U. Ledzewicz, Geometric Optimal Control, Interdisciplinary Applied Mathematics, vol. 38, Springer, 2012.

    [44]

    H. Schättler and U. Ledzewicz, Optimal Control for Mathematical Models of Cancer Therapies, Interdisciplinary Applied Mathematics, vol. 42, Springer, 2015.

    [45] Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. Science (2011) 331: 1565-1570.
    [46]

    S. V. Sharma et al., A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations, Cell, 141 (2010), 69–80.

    [47] On mathematical modeling of critical variables in cancer treatment (goals: better understanding of the past and better planning in the future). Bulletin of Mathematical Biology (1986) 48: 253-278.
    [48] Course of the immune reaction during the development of a malignant tumour. Biophysics (1980) 24: 917-923.
    [49]

    G. W. Swan, Applications of Optimal Control Theory in Medicine, Marcel Dekker, New York, 1984.

    [50] General applications of optimal control theory in cancer chemotherapy. IMA J. of Mathematical Applications in Medicine and Biology (1988) 5: 303-316.
    [51]

    A. Swierniak, Optimal treatment protocols in leukemia - modelling the proliferation cycle, Biomedical Systems Modelling and Simulation (Paris, 1988), 51–53, IMACS Ann. Comput. Appl. Math., 5, IMACS Trans. Sci. Comput. '88, Baltzer, Basel, 1989.

    [52] Cell cycle as an object of control. Journal of Biological Systems (1995) 3: 41-54.
    [53] Optimal control for a class of compartmental models in cancer chemotherapy. Int. J. Applied Mathematics and Computer Science (2003) 13: 357-368.
    [54] Optimal control problems arising in cell-cycle-specific cancer chemotherapy. Cell proliferation (1996) 29: 117-139.
    [55] Qualitative analysis of controlled drug resistance model - inverse Laplace and semigroup approach. Control and Cybernetics (1999) 28: 61-75.
    [56] Cancer chemotherapy optimization under evolving drug resistance. Nonlinear Analysis (2000) 47: 375-386.
    [57]

    G. Tonini, M. Imperatori, B. Vincenci, A. M. Frezza and D. Santini, Rechallenge therapy and treatment holiday: Different strategies in management of metastatic colorectal cancer, J. Experimental Clinical Cancer Research, 32 (2013), p92.

    [58] Optimal control of a mathematical model for cancer chemotherapy under tumor heterogeneity. Mathematical Biosciences and Engineering - MBE (2016) 13: 1223-1240.
    [59]

    S. Wang and H. Schättler, Optimal control for cancer chemotherapy under tumor heterogeneity, Discrete and Continuous Dynamical Systems, Series B, 48 (2018).

    [60] Back to the basics: the importance of concentration $\times$ time in oncology. J. of Clinical Oncology (1993) 11: 820-821.
  • This article has been cited by:

    1. Zamra Sajid, Morten Andersen, Johnny T. Ottesen, System dynamics of cancer in erythropoiesis with multiple EPO feedbacks , 2020, 36, 0883-7066, 447, 10.1002/sdr.1670
    2. Johnny T. Ottesen, Rasmus K. Pedersen, Marc J. B. Dam, Trine A. Knudsen, Vibe Skov, Lasse Kjær, Morten Andersen, Mathematical Modeling of MPNs Offers Understanding and Decision Support for Personalized Treatment, 2020, 12, 2072-6694, 2119, 10.3390/cancers12082119
    3. Morten Andersen, Hans C. Hasselbalch, Lasse Kjær, Vibe Skov, Johnny T. Ottesen, Global dynamics of healthy and cancer cells competing in the hematopoietic system, 2020, 326, 00255564, 108372, 10.1016/j.mbs.2020.108372
    4. Rasmus Kristoffer Pedersen, Morten Andersen, Vibe Skov, Lasse Kjær, Hans C Hasselbalch, Johnny T Ottesen, Thomas Stiehl, HSC Niche Dynamics in Regeneration, Pre-malignancy, and Cancer: Insights From Mathematical Modeling, 2022, 1066-5099, 10.1093/stmcls/sxac079
    5. Mia Brunetti, Michael C. Mackey, Morgan Craig, Understanding Normal and Pathological Hematopoietic Stem Cell Biology Using Mathematical Modelling, 2021, 7, 2198-7866, 109, 10.1007/s40778-021-00191-9
    6. Mia Brunetti, Isabella A. Iasenza, Adrianne L. Jenner, Noël J.-M. Raynal, Kolja Eppert, Morgan Craig, Mathematical modelling of clonal reduction therapeutic strategies in acute myeloid leukemia, 2024, 140, 01452126, 107485, 10.1016/j.leukres.2024.107485
    7. Thomas Stiehl, 2023, Chapter 73, 978-3-031-28048-1, 327, 10.1007/16618_2023_73
  • Reader Comments
  • © 2019 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(7310) PDF downloads(533) Cited by(4)

Figures and Tables

Figures(5)

Other Articles By Authors

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog